RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here:
CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases.
The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint.
The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
OSI Systems Receives $10 Million Order for Cargo and Vehicle Inspection Systems
HAWTHORNE, Calif.--(BUSINESS WIRE)-- OSI Systems, Inc. (the 'Company' or 'OSI Systems') (NASDAQ: OSIS) today announced that its Security division has received an order valued at approximately $10 million from an international customer to provide the Eagle ® M60 ZBx, an advanced, multi-technology, mobile inspection system with combinational imaging for scanning cargo and vehicles at seaports, border crossings, and security checkpoints. OSI Systems' President and CEO, Ajay Mehra, stated, 'We are excited to provide the M60 ZBx, one of our most innovative solutions for scanning cargo and vehicles, using transmission X-ray technology for deeper penetration inspection of dense cargo and Z Backscatter ® technology for enhanced detection of organic threats and contraband with photo-like imaging for easier image interpretation.' About OSI Systems OSI Systems is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications in the homeland security, healthcare, defense and aerospace industries. The Company combines more than 40 years of electronics engineering and manufacturing experience with offices and production facilities in more than a dozen countries to implement a strategy of expansion into selective end product markets. For more information on OSI Systems or its subsidiary companies, visit News Filter: OSIS-G Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to OSI Systems' current expectations, beliefs, and projections concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance and involve uncertainties, risks, assumptions, and contingencies, many of which are outside OSI Systems' control and which may cause actual results to differ materially from those described in or implied by any forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are based on currently available information and speak only as of the date on which they are made. OSI Systems assumes no obligation to update any forward-looking statement made in this press release that becomes untrue because of subsequent events, new information, or otherwise, except to the extent it is required to do so in connection with its ongoing requirements under Federal securities laws. For a further discussion of factors that could cause OSI Systems' future results to differ materially from any forward-looking statements, see the section entitled "Risk Factors" in OSI Systems' most recently filed Annual Report on Form 10-K and other risks described therein and in documents subsequently filed by OSI Systems from time to time with the Securities and Exchange Commission.
Business Wire
an hour ago
- Business Wire
Leonardo DRS Schedules Second Quarter 2025 Earnings Conference Call for July 30, 2025
ARLINGTON, Va.--(BUSINESS WIRE)--Leonardo DRS, Inc. (Nasdaq: DRS) has scheduled a conference call for Wednesday, July 30, 2025 beginning at 10:00 a.m. (ET) to discuss its second quarter 2025 results. The company plans to issue its quarterly earnings press release prior to the conference call. The live audio broadcast of Leonardo DRS's conference call with corresponding press release and supplemental information will be available on the company's investor relations website. To attend the conference call or webcast, participants should register online at A replay will be available on the company's website approximately two hours after the conclusion of the conference call and will remain available for 90 days. About Leonardo DRS Headquartered in Arlington, VA, Leonardo DRS, Inc. is an innovative and agile provider of advanced defense technology to U.S. national security customers and allies around the world. We specialize in the design, development and manufacture of advanced sensing, network computing, force protection, and electric power and propulsion, and other leading mission-critical technologies. Our innovative people are leading the way in developing disruptive technologies for autonomous, dynamic, interconnected, and multi-domain capabilities to defend against new and emerging threats. For more information and to learn more about our full range of capabilities, visit Forward-Looking Statements This communication contains statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements reflect current expectations, assumptions and estimates of future performance and economic conditions. The company cautions investors that any forward-looking statements are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements.
Business Wire
an hour ago
- Business Wire
Eagle Point Institutional Income Fund Reaches $200 Million Milestone and Delivers 35
GREENWICH, Conn.--(BUSINESS WIRE)--Eagle Point Institutional Income Fund (the 'Fund') today announced that total assets, inclusive of available borrowings under a revolving credit facility, have exceeded $200 million. The Fund recently paid its 35 th consecutive monthly cash distribution representing a 12.0% annualized distribution rate. 1 The Fund is managed by Eagle Point Credit Management LLC ('Eagle Point'), a specialist private credit asset manager with over $12 billion of assets under management. 2 The Fund's primary investment objective is to generate high current income and its secondary objective is to generate capital appreciation. The Fund seeks to achieve its investment objectives by investing primarily in equity and junior debt tranches of collateralized loan obligations ('CLOs'). CLOs are backed by portfolios of floating rate senior secured loans principally to American companies. The Fund's portfolio of 84 CLO equity investments provided exposure to 1,363 different companies across 61 different industries. 3 'We are pleased to deliver consistent monthly cash distributions to investors supported by the strong cash flow generated by our CLO portfolio,' said Thomas Majewski, the Fund's Chairman and Chief Executive Officer. 'CLO equity has proven to be a resilient asset class through multiple cycles. We are grateful to our investors who recognize both the merits of the asset class and Eagle Point's ability to deliver superior investment results.' The Fund is a non-traded closed-end fund registered under the Investment Company Act of 1940, and it currently offers its common shares on a continuous basis via monthly closings. About Eagle Point Credit Management LLC Eagle Point ® is an investment manager focused on specialized private credit strategies in inefficient markets, including Portfolio Debt Securities, 4 Regulatory Capital Relief transactions, Strategic Credit investments and CLO securities. Founded in 2012 by Thomas Majewski in partnership with Stone Point Capital, Eagle Point manages over $12 billion of assets for institutional and retail investors. Eagle Point is based in Greenwich, Connecticut and has over 100 professionals. Please visit for more information. Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Fund's filings with the U.S. Securities and Exchange Commission. The Fund undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Securities Disclosure This press release is provided for informational purposes only, does not constitute an offer to sell or a solicitation to purchase, securities of the Fund and is not a prospectus. Such offering is only made by the Fund's prospectus, which includes details as to the Fund's offering and other material information. Securities are offered through Eagle Point Securities LLC, a member of FINRA and SIPC and an affiliate of Eagle Point. Investing in the Fund involves the possible loss of some or all principal invested. Speak to your tax professional prior to investing. Please refer to the prospectus available at for additional information about the Fund. An investor should consider the investment objectives, risks and charges and expenses of the Fund carefully before investing. Risk Disclosures and Important Information The Fund is designed as a long-term investment, not a trading vehicle. Past performance is not indicative of, or a guarantee of, future performance. Common shares of the Fund are not traded on an exchange. The Fund may, but is not required to, offer to repurchase a limited number of shares, and there is no guarantee you will be able to sell your shares. An investment in the Fund's shares should be considered illiquid. The Fund invests a significant portion of its assets in CLO equity and junior debt securities; these may have more acute risks than other types of credit instruments. An investment in the Fund is speculative and entails substantial risk, including the possible loss of some or all of one's investment. There can be no assurance that the Fund's investment objectives will be achieved. An investment in the Fund is not appropriate for all investors and is not intended to be a complete investment program. The Fund utilizes leverage, which involves risk, including possible high volatility and declines in the Fund's NAV. The Fund invests primarily in below-investment grade or unrated securities, commonly called 'high yield' or 'junk' securities. Such investments may not pay interest or repay principal when due. ______________________________ 1 Annualized distribution rate reflects distributions paid during the month ending in May 2025 annualized and divided by the prior quarter end net asset value. The annualized distribution rate is not a guarantee of future returns and future performance may vary. The timing and frequency of distribution payments is not guaranteed. In considering returns, investors should bear in mind that historical performance is not a guarantee, projection or prediction and is not indicative of future results. Actual net returns in any given year may be lower than the historical returns. Investment return and principal value of any investment will fluctuate and may be worth more or less than the amount initially invested. Distribution payments are not guaranteed. Distributions may be comprised of any combination of 1) net investment income and/or 2) net capital gain, and, if the Fund distributes an amount in excess of net investment income and net capital gains, a portion of such distribution will constitute a return of capital. A distribution comprised in whole or in part by a return of capital does not necessarily reflect the Fund's investment performance and should not be confused with 'yield' or 'income.' A return of capital distribution may reduce the amount of investable funds. The actual components of the Fund's distributions for US tax reporting purposes can only be finally determined as of the end of each fiscal year of the Fund and are thereafter reported to shareholders on Form 1099-DIV. 2 AUM represents gross assets, inclusive of committed but undrawn capital, managed by Eagle Point and certain of its affiliates, as of May 31, 2025. 3 The information presented herein is on a look-through basis to the CLO equity held by the Fund as of March 31, 2025 (except as otherwise noted) and reflects the aggregate underlying exposure of the Fund based on the portfolios of those investments. The data is estimated and unaudited and is derived from CLO trustee reports received by the Fund relating to March 2025 and from custody statements and/or other information received from CLO collateral managers and other third-party sources. Information relating to the market price of underlying collateral is as of month end; however, with respect to other information shown, depending on when such information was received, the data may reflect a lag in the information reported. As such, while this information was obtained from third-party data sources, March 2025 trustee reports and similar reports, other than market price, it does not reflect actual underlying portfolio characteristics as of March 31, 2025 and this data may not be representative of current or future holdings. Industry categories are based on the S&P industry categorization of each obligor as reported in CLO trustee reports to the extent so reported. Certain CLO trustee reports do not report the industry category of all of the underlying obligors and where such information is not reported, it is not included in the summary look-through industry information shown. As such, the Fund's exposure to a particular industry may be higher than that shown if industry categories were available for all underlying obligors. In addition, certain underlying obligors may be re‐classified from time to time based on developments in their respective businesses and/or market practices. 4 Eagle Point defines 'Portfolio Debt Securities' as primarily debt and preferred equity securities or instruments (including debt and preferred securities which are convertible into common equity) issued by funds and investment vehicles, such as BDCs, registered closed-end investment companies, unregistered private funds, REITs and sponsors of such vehicles, to finance a portion of their underlying investment portfolios. Expand
